[go: up one dir, main page]

MX2020009234A - Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. - Google Patents

Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.

Info

Publication number
MX2020009234A
MX2020009234A MX2020009234A MX2020009234A MX2020009234A MX 2020009234 A MX2020009234 A MX 2020009234A MX 2020009234 A MX2020009234 A MX 2020009234A MX 2020009234 A MX2020009234 A MX 2020009234A MX 2020009234 A MX2020009234 A MX 2020009234A
Authority
MX
Mexico
Prior art keywords
type
heteroaryl compounds
irak inhibitors
uses hereof
hereof
Prior art date
Application number
MX2020009234A
Other languages
English (en)
Inventor
Nadia Brugger
Catherine Jorand-Lebrun
Theresa Johnson
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020009234A publication Critical patent/MX2020009234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I) y composiciones farmacéuticamente aceptables de los mismos, que son útiles como inhibidores de IRAK.
MX2020009234A 2018-04-05 2019-04-01 Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. MX2020009234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652981P 2018-04-05 2018-04-05
PCT/EP2019/058186 WO2019192962A1 (en) 2018-04-05 2019-04-01 Heteroaryl compounds as type ii irak inhibitors and uses hereof

Publications (1)

Publication Number Publication Date
MX2020009234A true MX2020009234A (es) 2020-10-12

Family

ID=66165920

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009234A MX2020009234A (es) 2018-04-05 2019-04-01 Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.

Country Status (14)

Country Link
US (1) US11873303B2 (es)
EP (1) EP3774797B1 (es)
JP (1) JP7328987B6 (es)
KR (1) KR102785107B1 (es)
CN (1) CN112236429B (es)
AU (1) AU2019249721B2 (es)
BR (1) BR112020018383A2 (es)
CA (1) CA3092625A1 (es)
IL (1) IL277408B2 (es)
MX (1) MX2020009234A (es)
SG (1) SG11202008162WA (es)
TW (1) TWI846690B (es)
WO (1) WO2019192962A1 (es)
ZA (1) ZA202005326B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019249721B2 (en) * 2018-04-05 2024-07-18 Merck Patent Gmbh Heteroaryl compounds as type II IRAK inhibitors and uses hereof
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
AU2019417833B2 (en) 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
JP7353682B2 (ja) * 2019-09-26 2023-10-02 深▲チェン▼市塔吉瑞生物医薬有限公司 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
WO2021226547A2 (en) * 2020-05-08 2021-11-11 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
CN115843272B (zh) 2020-05-08 2025-07-18 哈利亚治疗公司 Nek7激酶的抑制剂
EP4161933A1 (en) * 2020-06-08 2023-04-12 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
TW202400250A (zh) 2022-04-12 2024-01-01 美商健臻公司 Irak4調節劑於基因療法之用途(一)
CN117659022A (zh) * 2022-09-06 2024-03-08 苏州阿尔脉生物科技有限公司 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025067411A1 (zh) * 2023-09-28 2025-04-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
KR20190077610A (ko) 2010-07-13 2019-07-03 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
JP2016531870A (ja) * 2013-09-27 2016-10-13 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
TW201605847A (zh) 2013-11-08 2016-02-16 武田藥品工業股份有限公司 雜環化合物
WO2015164374A1 (en) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP3157521A4 (en) * 2014-06-20 2018-02-14 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
ES2841452T3 (es) * 2015-02-06 2021-07-08 Merck Patent Gmbh Macrociclos de piridazinona como inhibidores de IRAK y sus usos
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
JP6943876B2 (ja) * 2016-04-15 2021-10-06 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｒｅｔキナーゼ阻害剤としての複素環化合物
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US20190203253A1 (en) 2016-07-05 2019-07-04 University Of Saskatchewan Methods of identifying and treating cancer patients with an ephb6 deficiency
AU2019249721B2 (en) * 2018-04-05 2024-07-18 Merck Patent Gmbh Heteroaryl compounds as type II IRAK inhibitors and uses hereof

Also Published As

Publication number Publication date
BR112020018383A2 (pt) 2020-12-29
IL277408A (en) 2020-11-30
CA3092625A1 (en) 2019-10-10
IL277408B1 (en) 2024-04-01
AU2019249721A1 (en) 2020-09-17
KR20200140302A (ko) 2020-12-15
EP3774797A1 (en) 2021-02-17
RU2020135904A (ru) 2022-05-05
SG11202008162WA (en) 2020-09-29
WO2019192962A1 (en) 2019-10-10
US11873303B2 (en) 2024-01-16
JP7328987B2 (ja) 2023-08-17
US20210163487A1 (en) 2021-06-03
CN112236429A (zh) 2021-01-15
AU2019249721B2 (en) 2024-07-18
CN112236429B (zh) 2024-10-11
TW202005968A (zh) 2020-02-01
IL277408B2 (en) 2024-08-01
KR102785107B1 (ko) 2025-03-26
ZA202005326B (en) 2025-12-17
JP7328987B6 (ja) 2023-10-25
JP2021520356A (ja) 2021-08-19
TWI846690B (zh) 2024-07-01
EP3774797B1 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
CR20200393A (es) Picolinamidas como fungicidas
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MY210123A (en) Tlr7/8 antagonists and uses thereof
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
EP4609866A3 (en) Oxysterols and methods of use thereof
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2017009624A (es) Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
MY200641A (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds